Amneal Pharmaceuticals, Inc. reported a net revenue of $796.2 million for the three months ended June 30, 2026, marking a 9.9% increase from $724.5 million in the same period last year. The company's gross profit also saw a significant rise, reaching $334.5 million, up 16.9% from $286.3 million in the prior year. This growth in revenue was primarily driven by the Affordable Medicines segment, which contributed $489.9 million, reflecting a 13.0% increase due to new product launches and increased sales in women's health medicines. The Specialty segment also performed well, with a 16.6% increase in revenue to $149.3 million, largely attributed to strong sales of CREXONT® and BREKIYA® autoinjector.
In contrast, the AvKARE segment experienced a decline in revenue, falling 3.7% to $157.0 million, primarily due to reduced low-margin distribution sales. The overall operating income for the quarter was $129.8 million, a 16.5% increase from $111.4 million in the previous year. The company reported a net income of $69.6 million, a substantial increase of 95.5% compared to $35.6 million in the same quarter of 2025. This increase in profitability was supported by a significant reduction in the provision for income taxes, which dropped to $1.4 million from $16.1 million.
Amneal's financial performance for the first half of 2026 also showed positive trends, with total revenue reaching $1.52 billion, a 7.0% increase from $1.42 billion in the first half of 2025. The company’s gross profit for this period was $654.6 million, up 20.7% year-over-year. The increase in revenue was driven by growth in both the Affordable Medicines and Specialty segments, while the AvKARE segment saw a decline. The net income for the first six months was $147.6 million, a 145.1% increase from $60.2 million in the prior year.
Strategically, Amneal announced its agreement to acquire Kashiv BioSciences, LLC, a transaction valued at $375 million in cash and stock, with potential additional payments based on regulatory milestones. This acquisition is expected to close in the third quarter of 2026 and is anticipated to enhance Amneal's product portfolio and market position. Additionally, the company has been actively managing its operational costs, with a focus on reducing research and development expenses, which decreased by 12.0% in the first half of 2026 compared to the previous year.
Looking ahead, Amneal anticipates continued growth driven by new product launches and market expansion, despite facing challenges such as price erosion and competitive pressures in the pharmaceutical industry. The company is also preparing for potential impacts from recent changes in trade policies and tariffs, which could affect its cost structure and market dynamics. Overall, Amneal's financial outlook remains positive, supported by its strategic initiatives and operational efficiencies.
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in developing, manufacturing, marketing, and distributing a broad portfolio of essential medicines. Its business segments include Affordable Medicines (generics, injectables, biosimilars), Specialty branded pharmaceuticals focused on central nervous system and endocrine disorders, and AvKARE, a pharmaceutical distributor serving U.S. government and institutional markets. Amneal leverages complex formulations, vertical integration, and regulatory expertise to deliver cost-effective, high-value pharmaceutical products primarily in the U.S., India, and Ireland.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov